Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iBio reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines.
Subscribe to our email newsletter
iBio intellectual property vice-president Dr Wayne Fitzmaurice noted that the invention covered by this patent enables increased efficiency in the expression of a range of commercially important proteins.
"The allowed claims cover both composition of matter and uses of the technology for both therapeutic products and vaccines," Dr Fitzmaurice added.
The company recently launched a new subsidiary, iBio Brazil, to facilitate entry of biosimilar therapeutics in Brazil. iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 in Brazil to develop a recombinant yellow fever vaccine based upon iBio technology.
iBio’s success in Brazil is expected to serve as a template for other iBio projects worldwide.
The allowed patent application, "Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides," is based on an invention developed by scientists at the company’s research and technology collaborator, the Fraunhofer USA Center for Molecular Biotechnology.
The invention is owned by iBio. When this patent issued, it will add to the company’s fusion protein and iBioModulator patents in the US, Australia, Canada, India and Europe (Germany, France, Italy, Ireland, Spain, and Great Britain).